Table 2.
Frequency of irAE (all patients)
| Patients with irAE, n (%) |
Patients with systemic steroid therapy, n (%) | Patients with treatment discontinuation, n (%) | |||
|---|---|---|---|---|---|
| Total | Grades 1–2 | Grade >3 | |||
| Any irAE | 97 (57.7) | 90 (53.6) | 24 (14.3) | 27 (16.1) | 28 (16.7) |
| Dermatological irAE | 79 (47.0) | 77 (45.8) | 2 (1.2) | 8 (4.8) | 5 (3.0) |
| Hepatobiliary irAE | 24 (14.3) | 12 (7.1) | 12 (7.1) | 11 (6.5) | 11 (7.1) |
| Endocrine irAE | 16 (9.5) | 14 (8.3) | 2 (1.2) | 1 (0.6) | 2 (1.2) |
| Gastrointestinal irAE | 15 (8.9) | 10 (6.0) | 5 (3.0) | 4 (2.4) | 4 (2.4) |
| Pneumonitis irAE | 9 (5.4) | 5 (3.0) | 4 (2.4) | 8 (4.8) | 8 (4.8) |
| Musculoskeletal irAE | 3 (1.8) | 3 (1.8) | − | 1 (0.6) | − |
| Hematology irAE | 2 (1.2) | 1 (0.6) | 1 (0.6) | 1 (0.6) | 1 (0.6) |
| Neurology irAE | 1 (0.6) | 1 (0.6) | − | − | 1 (0.6) |
| Renal irAE | 1 (0.6) | − | 1 (0.6) | 1 (0.6) | 1 (0.6) |
| Others irAE | 11 (6.5) | 10 (6.0) | 1 (0.6) | 2 (1.2) | − |
| 1 irAE | 61 (36.3) | ||||
| 2 irAE | 22 (13.1) | ||||
| ≥3 irAE | 14 (8.3) | ||||
irAE, immune-related adverse event.